Aegirbio
0.496 SEK +0.92%Be the first to follow this company
Aegirbio operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and mainly includes drugs for the treatment of multiple sclerosis. In addition to the main business, associated ancillary services are offered. The business is run in collaboration with other pharmaceutical actors, where the largest presence is found in the Nordic region.
Revenue
90K
EBIT %
-62,400 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
AEGIR
Daily low / high price
0.492 / 0.536
SEK
Market cap
15.3M SEK
Turnover
48.32K SEK
Volume
95K
Financial calendar
Extraordinary general meeting
2024-04-26
Interim report
2024-05-17
General meeting
2024-06-28
Interim report
2024-08-23
Interim report
2024-11-15
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Abreos Sweden | 13.0 % | 13.0 % |
Försäkringsbolaget Avanza Pension | 5.8 % | 5.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
AegirBio AB:s dotterbolag påkallar skiljeförfarande mot Salofa Oy
Kallelse till extra bolagsstämma i AegirBio AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools